Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Fundamentals
Mkt Cap
$357.69M
Volume
-
52W High
$13.25
52W Low
$5.65
PE Ratio
-82.90
Avg. Volume
194,860.63
EPS (Annual)
-$0.3409
P/B
8.77
Rev/Employee
$1,275,485.71
Earnings
Nov 12
50
Neutral Sentiment
How do you feel about FENC?
focafoca99
$FENC communicated positive Phase 2 STS-J01 results for PEDMARK® in Japan, meeting the primary endpoint and showing hearing protection.